Advanced search
Publication Cover
International Journal of General Medicine Volume 14, 2021 - Issue
Submit an article Journal homepage
91
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Elevated SARS-Cov-2-Specific IgM Levels Indicate Clinically Unfavorable Outcomes in Patients with COVID-19: A Retrospective Cohort Study

Zhiquan Hu1 Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
,
Jingjing Li2 Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
,
Chunguang Yang1 Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3882-4940
ORCID Icon,
Fen Chen3 Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of ChinaCorrespondence[email protected]
,
Zhihua Wang1 Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
,
Ping Lei4 Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
&
Guanxin Shen4 Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
 show all
Pages 10429-10438 | Published online: 29 Dec 2021

References

  • Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7
  • Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017
  • World Health Organization. Novel coronavirus (COVID-19) situation. Available from: https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd. Accessed December 21, 2021.
  • Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149–150. doi:10.1038/d41573-020-00016-0
  • Dibo M, Battocchio EC, Dos Santos Souza LM, et al. Antibody therapy for the control of viral diseases: an update. Curr Pharm Biotechnol. 2019;20(13):1108–1121. doi:10.2174/1389201020666190809112704
  • Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–539. doi:10.1007/s00281-017-0629-x
  • Gronvall G, Connell N, Kobokovich A, et al. Developing a National strategy for serology (antibody testing) in the United States. 2020; Available from: https://www.centerforhealthsecurity.org/our-work/publications/developing-a-national-strategy-for-serology-antibody-testing-in-the-US. Accessed December 21, 2021.
  • Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020. doi:10.1002/jmv.25727
  • To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565–574. doi:10.1016/S1473-3099(20)30196-1
  • Thevarajan I, Nguyen THO, Koutsakos M, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020;26(4):453–455. doi:10.1038/s41591-020-0819-2
  • Li G, Chen X, Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med. 2003;349(5):508–509. doi:10.1056/NEJM200307313490520
  • Kucharski AJ, Russell TW, Diamond C, et al. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect Dis. 2020;20(5):553–558. doi:10.1016/S1473-3099(20)30144-4
  • Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3
  • Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
  • Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi:10.1016/S2213-2600(20)30076-X
  • Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768. doi:10.1093/cid/ciaa248
  • Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;71(16):2027–2034. doi:10.1093/cid/ciaa344
  • Nawata Y, Stall AM, Herzenberg LA, et al. Surface immunoglobulin ligands and cytokines differentially affect proliferation and antibody production by human CD5+ and CD5−B lymphocytes. Int Immunol. 1990;2(7):603–614. doi:10.1093/intimm/2.7.603
  • Weilie chen W, Lan Y, Yuan X, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg Microbes Infect. 2020;9(1):469–473. doi:10.1080/22221751.2020.1732837
  • Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol. 2020;94(5). doi:10.1128/JVI.02015-19

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.